keyword
MENU ▼
Read by QxMD icon Read
search

Absssi

keyword
https://www.readbyqxmd.com/read/29136035/comparative-efficacy-and-safety-of-antibiotics-used-to-treat-acute-bacterial-skin-and-skin-structure-infections-results-of-a-network-meta-analysis
#1
Julian F Guest, Jaime Esteban, Anton G Manganelli, Andrea Novelli, Giuliano Rizzardini, Miquel Serra
OBJECTIVE: This NMA compared the efficacy and safety between IV antibiotics that are used in the current standard of care for managing adult patients (≥18 years of age) with ABSSSI. METHODS: Comparators were chosen on the basis that both direct and indirect comparisons between the interventions of interest could be performed. Outcomes of the analysis were selected on the basis that they are frequently measured and reported in trials involving ABSSSI patients, and only published randomised control trials of any size and duration and with any blinding status were eligible for inclusion in the analysis...
2017: PloS One
https://www.readbyqxmd.com/read/29133566/use-of-pharmacokinetic-and-pharmacodynamic-analyses-to-determine-the-optimal-fixed-dosing-regimen-of-iclaprim-for-treatment-of-serious-gram-positive-infections
#2
Thomas Lodise, John Bosso, Colleen Kelly, Paul J Williams, James R Lane, David B Huang
Iclaprim is a bacterial dihydrofolate reductase inhibitor that is currently being evaluated in two Phase 3 trials for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Prior animal infection models studies suggest that the pharmacokinetic and pharmacodynamics (PK/PD) drivers for efficacy are area under the curve from 0-24 hours at steady state (AUC0-24hss), AUC/minimum inhibitory concentration (MIC), and time above the MIC during the dosing interval (T > MIC) while QTc prolongation was associated to maximal concentration at steady state (Cmaxss) in a thorough QTc Phase 1 study...
November 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29059465/what-is-old-is-new-again-delafloxacin-a-modern-fluoroquinolone
#3
Jonathan C Cho, Matthew P Crotty, Bryan P White, Marylee V Worley
Delafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults using dosage regimens of 300 mg intravenously every 12 hours, 450 mg orally every 12 hours, or switching from intravenous to oral regimens for a 5 to 14 day treatment duration. Dosage adjustments in patients with severe renal dysfunction (estimated glomerular filtration rate [eGFR] = 15-29 ml/min/1.73m(2) ) are not required for oral doses but should be decreased to 200 mg intravenously every 12 hours in patients requiring parenteral therapy...
October 23, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28980484/rate-and-incidence-of-adverse-reactions-associated-with-ceftaroline-exposure-importance-of-cutaneous-manifestations
#4
Jeffrey W Jansen, Ryan P Moenster
BACKGROUND: Ceftaroline is a broad-spectrum, methicillin-resistant Staphylococcus aureus (MRSA)-active β-lactam approved for acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia. Because of its favorable spectrum and pharmacokinetics, ceftaroline is frequently utilized for infections such as osteomyelitis and endocarditis. Ceftaroline has been associated with neutropenia, but evaluation of other adverse events remains limited. OBJECTIVE: To describe the rates and types of ceftaroline-associated adverse events and determine if patients' baseline allergies affect the rates of an adverse event...
October 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28959445/management-of-acute-bacterial-skin-and-skin-structure-infections-with-a-focus-on-patients-at-high-risk-of-treatment-failure
#5
REVIEW
Abraham Pulido-Cejudo, Mario Guzmán-Gutierrez, Abel Jalife-Montaño, Alejandro Ortiz-Covarrubias, Jose Luis Martínez-Ordaz, Héctor Faustino Noyola-Villalobos, Luis Mauricio Hurtado-López
Over the last 25 years, the terminology of skin and soft tissue infections, as well as their classification for optimal management of patients, has changed. The so-called and recently introduced term 'acute bacterial skin and skin structure infections' (ABSSSIs), a cluster of fairly common types of infection, including abscesses, cellulitis, and wound infections, require an immediate effective antibacterial treatment as part of a timely and cautious management. The extreme level of resistance globally to many antibiotic drugs in the prevalent causative pathogens, the presence of risk factors of treatment failure, and the high epidemic of comorbidities (e...
September 2017: Therapeutic Advances in Infectious Disease
https://www.readbyqxmd.com/read/28668679/novel-application-of-published-risk-factors-for-methicillin-resistant-s-aureus-in-acute-bacterial-skin-and-skin-structure-infections
#6
Kimberly C Claeys, Evan J Zasowski, Abdalhamid M Lagnf, Donald P Levine, Susan L Davis, Michael J Rybak
MRSA ABSSSIs are associated with a significant clinical and economic burden, however rapid identification of MRSA remains a challenge. This study aimed to use a novel method of predictive modeling to determine those at highest risk of MRSA ABSSSIs. Risk factors for MRSA were derived from a combination of previously published literature and multivariable logistic regression of individual patient data (IPD) using the "adaptation method." A risk-scoring tool was derived from weight-proportional integer-adjusted coefficients of the predictive model...
June 28, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28630189/in-vitro-activity-of-delafloxacin-and-microbiological-response-against-fluoroquinolone-susceptible-and-nonsusceptible-staphylococcus-aureus-isolates-from-two-phase-3-studies-of-acute-bacterial-skin-and-skin-structure-infections
#7
S McCurdy, L Lawrence, M Quintas, L Woosley, R Flamm, C Tseng, S Cammarata
Delafloxacin is an investigational anionic fluoroquinolone antibiotic with broad-spectrum in vitro activity, including activity against Gram-positive organisms, Gram-negative organisms, atypical organisms, and anaerobes. The in vitro activity of delafloxacin and the percent microbiological response in subjects infected with fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates were determined from two global phase 3 studies of delafloxacin versus vancomycin plus aztreonam in patients with acute bacterial skin and skin structure infections (ABSSSI)...
September 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28543367/successful-treatment-of-methicillin-susceptible-staphylococcus-aureus-osteomyelitis-with-oritavancin
#8
Dino J Delaportas, Sandy J Estrada, Matthew Darmelio
Staphylococcus aureus remains the most common causative pathogen in osteomyelitis. New or alternative therapies are often needed to treat S. aureus infections adequately in patients with drug allergies, treatment failures, or drug interactions. Oritavancin is a novel long-acting lipoglycopeptide approved by the U.S. Food and Drug Administration in 2014 for the treatment of acute bacterial skin and skin structure infections. With a terminal half-life of 8-10 days, oritavancin dosing regimens with infrequent parenteral administration now exist to treat infectious diseases such as osteomyelitis that would otherwise require daily dosing of intravenous antimicrobials for weeks; however, clinical experience is lacking...
August 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28480266/efficacy-and-safety-of-oritavancin-relative-to-vancomycin-for-patients-with-acute-bacterial-skin-and-skin-structure-infections-absssi-in-the-outpatient-setting-results-from-the-solo-clinical-trials
#9
Thomas P Lodise, Mark Redell, Shannon O Armstrong, Katherine A Sulham, G Ralph Corey
BACKGROUND: The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatient setting in the Phase 3 SOLO clinical trials. METHODS: SOLO I and SOLO II were 2 identically designed comparative, multicenter, double-blind, randomized studies to evaluate the efficacy and safety of a single 1200-mg dose of intravenous (IV) oritavancin versus 7-10 days of twice-daily IV vancomycin for the treatment of ABSSSI...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28406838/managing-acute-bacterial-skin-and-skin-structure-infections-focus-on-new-lipoglycopeptides
#10
Allison M Bell, S Travis King, Katie E Barber, Kim G Adcock, Jamie L Wagner, Kayla R Stover
Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.V. available standard therapy options.
May 12, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28373199/efficacy-safety-and-tolerability-of-gepotidacin-gsk2140944-in-the-treatment-of-patients-with-suspected-or-confirmed-gram-positive-acute-bacterial-skin-and-skin-structure-infections
#11
William O'Riordan, Courtney Tiffany, Nicole Scangarella-Oman, Caroline Perry, Mohammad Hossain, Teri Ashton, Etienne Dumont
Gepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial agent which has in vitro activity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs). This phase 2, randomized, 2-part, multicenter, dose-ranging, response-adaptive study with optional intravenous-oral switch evaluated the efficacy and safety of gepotidacin for the treatment of Gram-positive ABSSSIs in 122 adult patients in the United States. The study had a double-blind phase (part 1; intravenous [750 mg or 1,000 mg every 12 h {q12h}]) and an open-label phase (part 2; intravenous [750 mg q12h, 1,000 mg q12h, or 1,000 q8h])...
June 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28264845/clinical-response-of-tedizolid-versus-linezolid-in-acute-bacterial-skin-and-skin-structure-infections-by-severity-measure-using-a-pooled-analysis-from-two-phase-3-double-blind-trials
#12
Taylor Sandison, Carisa De Anda, Edward Fang, Anita F Das, Philippe Prokocimer
Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In a pooled analysis of 1,333 ABSSSI patients from the ESTABLISH clinical trials, treatment with tedizolid or linezolid demonstrated similar early and posttherapy clinical responses in nonsevere and severe disease, irrespective of the parameters used to measure ABSSSI severity. Shorter 6-day treatment of ABSSSI, including those that were severe, with tedizolid phosphate demonstrated efficacy comparable to that of 10-day treatment with linezolid...
May 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28179245/ceftaroline-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-bacteremia
#13
Bryan Pinckney White, Katie E Barber, Kayla R Stover
PURPOSE: The utility of ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) is reviewed. SUMMARY: Ceftaroline was originally approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs) but recently received an additional approval for the treatment of S. aureus bacteremia (SAB) associated with ABSSSIs. Ceftaroline has demonstrated efficacy for the treatment of MRSAB, including isolates with elevated minimum inhibitory concentrations to conventional therapy when used alone or in combination with other agents...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28140693/pharmacokinetic-drug-evaluation-of-tedizolid-for-the-treatment-of-skin-infections
#14
REVIEW
Darrell McBride, Tamara Krekel, Kevin Hsueh, Michael J Durkin
Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Although tedizolid shares many similar properties with linezolid, another oxazolidinone used to treat ABSSSI, the two antibiotics have several key differences. Areas covered: This review provides a detailed summary of the overall pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of tedizolid for the treatment of ABSSSI. Expert opinion: Compared to other antibiotics used for ABSSSI, tedizolid has several advantages...
March 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28131729/ceftaroline-fosamil-monotherapy-for-methicillin-resistant-staphylococcus-aureus-bacteremia-a-comparative-clinical-outcomes-study
#15
COMPARATIVE STUDY
Samia Arshad, Vanthida Huang, Pamela Hartman, Mary B Perri, Daniela Moreno, Marcus J Zervos
OBJECTIVES: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, its use has been subject to scrutiny due to failure in severe infections. Ceftaroline fosamil (CPT-F) is approved for MRSA acute bacterial skin and skin structure infections, but not for bloodstream infections. The clinical outcomes of treatment with CPT-F in patients with MRSA bacteremia were evaluated. METHODS: Patients diagnosed with MRSA bacteremia at Henry Ford Hospital in Detroit, Michigan, USA, involving isolates with a vancomycin minimum inhibitory concentration ≥1...
April 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28078655/single-dose-oritavancin-compared-to-standard-of-care-iv-antibiotics-for-acute-bacterial-skin-and-skin-structure-infection-in-the-outpatient-setting-a-retrospective-real-world-study
#16
Patrick J Anastasio, Pete Wolthoff, Annmarie Galli, Weihong Fan
INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28061827/systematic-review-and-network-meta-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-mrsa
#17
Rachael McCool, Ian M Gould, Jacqui Eales, Teresa Barata, Mick Arber, Kelly Fleetwood, Julie Glanville, Teresa L Kauf
BACKGROUND: Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparative effectiveness of tedizolid and other antibacterials indicated for the treatment of ABSSSI caused by MRSA...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27993854/activities-of-omadacycline-and-comparator-agents-against-staphylococcus-aureus-isolates-from-a-surveillance-program-conducted-in-north-america-and-europe
#18
Michael A Pfaller, Paul R Rhomberg, Michael D Huband, Robert K Flamm
Omadacycline is a new broad-spectrum aminomethylcycline in late-stage clinical development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia as a once-daily formulation taken orally or intravenously. In this study, omadacycline and comparator agents were tested against 502 isolates of Staphylococcus aureus selected from a 2014 global surveillance program, and the results were compared with those for 7,740 isolates from a 2010 surveillance program. For the 2014 isolates, testing was completed on 252 isolates from Europe and 250 isolates from North America...
March 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27988870/single-dose-dalbavancin-a-review-in-acute-bacterial-skin-and-skin-structure-infections
#19
REVIEW
Karly P Garnock-Jones
Intravenous dalbavancin (Dalvance(®), Xydalba(®)), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48-72 h) and low rates of adverse events...
January 2017: Drugs
https://www.readbyqxmd.com/read/27970803/cost-minimization-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-sub-structure-infections-absssi-in-greece
#20
R Insinga, E Dalakaki, M P Retsa, A Karokis, E M Sarpong
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
15671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"